Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships

Oxidative Medicine and Cellular Longevity

Volumn 2, Issue 4, 2009, Pages 181-190

  Kovacic, Peter ^a   Somanathan, Ratnasamy ^b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b TIJUANA INSTITUTE OF TECHNOLOGY   (Mexico)

Author keywords

Catechol; Cell signaling; Electrochemistry; Mechanism; Mescaline; Metabolism; Neuropharmacology; Quinone; Receptor; Redox; SAR

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; BENZODIAZEPIN 2 ONE DERIVATIVE; CATECHOL; CHLORPROMAZINE; DIAZEPAM; DOPA; DRUG METABOLITE; ETOPOSIDE; MESCALINE; NORADRENALIN; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PSILOCIN; PSILOCYBINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SEROTONIN RECEPTOR;

ACTION POTENTIAL; ARTICLE; BEHAVIOR; BINDING AFFINITY; BRAIN CELL; CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM; CONCEPTUAL FRAMEWORK; DEMETHYLATION; DENDRITE; DRUG ABUSE; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROCHEMISTRY; ELECTROENCEPHALOGRAM; ELECTRON TRANSPORT; LIMBIC SYSTEM; MALE; NERVE TRACT; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTON TRANSPORT; PSYCHOSIS; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SPIKE; STEREOCHEMISTRY; STIMULUS; STRUCTURE ACTIVITY RELATION;

CATECHOLS; CENTRAL NERVOUS SYSTEM; ELECTRON TRANSPORT; MESCALINE; OXIDATION-REDUCTION; PROTEIN BINDING; QUINONES; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

BASIDIOMYCOTA;

EID: 77953408972     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.2.4.9380     Document Type: Article

References (89)

1. Mc Laughlin JL. Peyote: an introduction. Lloydia 1973; 36:1-8.
2. Paul AG. Biosynthesis of the peyote alkaloids. Lloydia 1973; 36:36-45.
3. Lundstöm J, Agurell S. A complete biosynthetic sequence from tyrosine to mescaline. Tetrahedron Lett 1969; 3371-4.
4. Kapadia GJ, Vaishnav YN, Fayez MBE. Peyote alkaloids IX: Identification and synthesis of demethylmescaline, a plausible intermediate in the biosynthesis of the cactus alkaloids. J Pharmaceut Sci 1969; 58:1157-9.
5. Soderquist JA, Kock I, Estrella ME. Reductive cleavage of acetals and ketals with 9-borabicyclo[3.3.1]nonane. Org Proc Res Develop 2006; 10:1076-9.
6. 6-1,2,3-trimethoxybenzene) chromium complex. Inorg Chim Acta 2000; 302:693-7.
7. Tsao M. A new synthesis of mescaline. J Am Chem Soc 1951; 73:5495-6.
8. Max E, Ramirez F. The reduction of β-nitrostyrene with lithium aluminum hydride. Helv Chim Acta 1950; 33:912-6.
9. Banholzer K, Campbell TW, Schimid H. Synthesis of mescaline, N-methyl- and,Ndimethylmescaline. Helv Chim Acta 1952; 35:1577-88.
10. Kovacic P, Becvar LE. Mode of action of anti-infective agents: emphasis on oxidative stress and electron transfer. Curr Pharmaceut Des 2000; 6:143-67. (Pubitemid 30395843)
11. Kovacic P, Osuna JA. Mechanisms of anticancer agents: emphasis on oxidative stress and electron transfer. Curr Pharmaceut Des 2000; 6:277-309. (Pubitemid 30412684)
12. Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001; 8:773-96. (Pubitemid 32427906)
13. Kovacic P, Jacintho JD. Reproductive toxins: pervasive theme of oxidative stress and electron transfer. Curr Med Chem 2001; 8:863-92. (Pubitemid 32427914)
14. Kovacic P, Sacman A, Wu-Weis M. Nephrotoxins: widespread role of oxidative stress and electron transfer. Curr Med Chem 2002; 9:823-47.
15. Poli G, Cheeseman KH, Dianzani MV, Slater TF. Eds. Free Radicals in the Pathogenesis of Liver Injury, Pergamon, New York 1989.
16. Kovacic P, Thurn LA. Cardiovascular toxins from the perspective of oxidative stress and electron transfer. Curr Vasc Pharmacol 2005; 3:107-17.
17. Kovacic P, Somanathan R. Neurotoxicity: The broad framework of electron transfer, oxidative stress and protection by antioxidants. Curr Med Chem-CNS Agents 2005; 5:249-58. (Pubitemid 41702296)
18. Kovacic P, Pozos RS, Somanathan R, Shangari R, O'Brien PJ. Mechanism of mitochondrial uncouplers, inhibitors and toxins: focus on electron transfer, free radicals and structure-activity relationships. Curr Med Chem 2005; 5:2601-23.
19. Kovacic P, Cooksy AL. Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med Hypotheses 2005; 64:366-7.
20. Kovacic P, Somanathan R. Ototoxicity and noise trauma: reactive oxygen species, cell signaling, electrical effects and protection by antioxidants. Practical medical aspects Med Hypotheses 2008; 70:914-23.
21. Kovacic P, Somanathan R. Integrated approach to immunotoxicity: electron transfer, reactive oxygen species, antioxidants, cell siganling and receptors. J Recept Signal Transduct 2008; 28:323-46.
22. Kovacic P, Somanathan R. Unifying mechanism for eye toxicity: electrón transfer, reactive oxygen species, antioxidant benefits, cell signaling and cell membranes. Cell Memb Free Radic Res 2008; 1:56-69.
23. Kovacic P, Somanathan R. Pulmonary toxicity and environmental conatamination; radicals, electron transfer and protection by antioxidants. In Reviews of Environmantal Contamination and Toxicology Whitcare DM, ed., Springer NY 2009; 201:41-69.
24. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine, Oxford UP, New York 1999.
25. Kovacic P, Pozos RS. Review: Bioelectronome: Integrated approach to receptor chemistry, radicals electrochemistry, cell signaling and physiological effects based on electron transfer. J Recept Signal Transduct 2007; 27:261-94.
26. Block W, Block K, Patzig B. Physiology of the 14C-radioactive mescaline in animal experiment II. Distribution of radioactivity in organs in relation to time. Z Physiol Chem 1952; 290:230-6.
27. Harley-Mason J, Laird AH, Smythies JR. The metabolism of mescaline in the human; delayed clinical reactions to mescaline. Conf Neurolog 18:152-5.
28. Charlampous KD, Walker KE, Kinross-Wright J. Metabolic fate of mescaline in man. Psychopharmacol (Berlin) 1966; 9:48-63.
29. Ratcliffe J, Smith P. Metabolism of mescaline. Chem Ind (London) 1958; 1159.
30. Friedhoff AJ, Goldstein M. New developments in metabolism of mescaline and related amines. Ann NY Acad Sci 1961; 95:5-13.
31. Daly J, Axelrod J, Witkop B. Methylation and demethylation in relation to the in vitro metabolism of mescaline. Ann NY Acad Sci 1962; 96:37-43.
32. Charalampous KD, Orengo A, Walker KE, Wright JK. Metabolic fate of 3,4,5-trimethoxyphenyl-ethylamine (mescaline) in humans: isolation and identification of 3,4,5-trimethoxyphenylacetic acid. J Pharmacol Exper Therapeut 1964; 145:242-6.
33. Neff N, Rossi GV, Chase GD, Rabinowitz JL. Distribution and metabolism of mescaline in the cat brain. J Pharmacol Exper Therapeut 1964; 144:1-7.
34. Wantanabe K, Kayano Y, Matsunaga T. Trimethoxyphenylacetaldehyde, an intermediate metabolite of mescaline, is a substrate for microsomal aldehyde oxgenase in the mouse liver. Biol Pharm Bull 1995; 18:696-9.
35. Demisch L, Kaczmarczyk P, Seiler N. 3,4,5-Trimethoxybenzoic acid, a new mescaline metabolite in humans. Drug Metab Dispos 1978; 6:507-9.
36. Datta RK, Ghosh JJ. Mescaline-induced changes of brain cortex ribosomes. Mescaline demethylase of brain cortex soluble supernatant. Naunyn Schmiedebergs Arch Pharmacol 1977; 296:297-300.
37. Mokrasch LC, Stevenson I. The metabolism of mescaline with a note on correlations between metabolism and psychological effects. J New Ment Dis 1959; 129:177-83.
38. Axelrod J. The enzymic cleavage of aromatic ethers. Biochem J 1956; 63:634-9.
39. Anonymous. Mescaline, Wikipedia encyclopedia 2008; http://en.wikipedia. org/wiki/Mescaline.
40. Smythies GR, Bradley RG, Johnston VS, Benington F, Morin RD, Clark LC Jr. Structure activity relationship studies on mescaline 3. The influence of the methoxy groups. Psychopharmacologia 1967; 10:379-87.
41. Shulgin T. Mescaline: The chemistry and pharmacology of its analogs. Lloydia 1973; 36:46-58.
42. Nichols DE. Structure-activity relationships of phenyethylamine hallucinogens. J Pharmaceut Sci 1981; 70:839-47.
43. Monte MP, Waldman ST, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE. Dihydrobenzofuran analogues of hallucinogens 4. Mescaline derivatives. J Med Chem 1997; 40:2997-3008.
44. Glennon RA. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 1999; 64:43-67.
45. Shulgin A, Shulgin A. PIHKAL a chemical love story. Berkeley, CA: Transform Press 1991.
46. Nichols DE. Hallucinogens. Pharmacol Therapeut 2004; 101:131-81.
47. Jacintho J, Kovacic P. Neurotransmission and neurotoxicity by nitric oxide, catecholamines and glutamate. Unifying themes of reactive oxygen species and electron transfer. Curr Med Chem 2003; 10:2693-703.
48. Kovacic P. Unifying electron transfer mechanism for psilocybin and psilocin. Med Hypotheses 2009; In press.
49. Blaschko H, Levine WG. Enzymatic oxidation of psilocine and other hydroxyindoles. Biochem Pharmacol 1960; 3:168-9.
50. Horita A, Weber LG. The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol 1961; 7:47-54.
51. Passie T, Seifert G, Schneider U, Enrich HM. The pharmacology of psilocybin. Addict Biol 2002; 7:357-64.
52. 2C receptors. Naunyn Schmiedeberg's Arch Pharmacol 1999; 359:1-6.
53. Davis WM, Bedford JA, Buelke JI, Guinn MM, Hatoum HT, Waters IW, et al. Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines and mescaline in rodents, dogs and monkeys. Toxicol Appl Pharmacol 1978; 45:49-62.
54. Beyerstein BL, Dal Cason TA, Franzosa ES, Hugel J, Kalchik M, Laing R, et al. Hallucinogens. A Forensic Handbook. New York, Academic Press 2003.
55. Pàlenicek T, Balíková M, Bubeníkovà- Valešovà, Horàcek J. Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacol 2008; 196:51-62.
56. Hollister LE. Effects of hallucinogens in humans. In Jacobs BL, (Ed.,) Hallucinogens: neurochemical, behavioral and clinical perspective. New York, Raven Press 1984; 19033.
57. Hermie L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, et al. Mescaline-induced psychopathological, neurophsiological and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32:976-91.
58. Appel JB, Callahan PM. Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol 1989; 159:41-6.
59. Gonzalez-Maeso J, Weisstaub N, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53:439-52.
60. Dill RE. Mescaline: receptor interaction in the rat striatum. Arch Int Pharmacodyn Ther 1974; 195:320-9.
61. Walters GC. Stereochemical requirements of the mescaline receptor. Nature 1972; 238:96-8.
62. 2A receptor. J Med Chem 2006; 49:4269-74.
63. Kovacic P. Bioelectrostatics: review of widespread importance in biochemistry. J Electrostat 2008; 66:124-9.
64. Wikler A. Clinical and electroencephalographic studies on the effects of mescaline, N-allylnormorphine and morphine in man; a pharmacologic analysis of the functions of the spontaneous electrical activity of the cerebral cortex. J Nerv Ment Dis 1954; 120:157-75.
65. Ramos JG. The mescaline or strychnine spikes as a tool for physiological and pharmacological studies. Acta Physiol Lat Am 1977; 27:16-30.
66. Ramos JG. A depressant cortical reaction induced by afferent stimulation. Acta Physiol Lat Am 1976; 26:38-50.
67. Ferri S, Santagostino A, Braga PC. Development of tolerance to the antinociceptive effect of mescaline intraventricularly administered to rabbits. Psychopharmacology 1976; 47:261-5.
68. Ferri S, Santagostino A, Braga PC. Cross tolerance to antinociception elicited by intracerebroventricular administration of mescaline and morphine to rabbits, and EEG correlates. Psychopharmacology 1976; 47:267-9.
69. Shull RN, Sbordone RJ, Gorelick DA. EEG correlates of mescaline-induced pathological aggression in rats. Physiolog Psycholog 1981; 9:208-12.
70. Aghjanian GK. Mescaline and LSD facilitate the activation of locus ceruleus neurons by peripheral stimuli. Brain Res 1980; 186:492-8.
71. Beebe SJ, Fox PM, Rec LJ. Nanosecond, high-intensity pulsed electric fields induce apoptosis in living cells. FASEB 2003; 17:1493-5.
72. Frey AH. Electromagnetic field interaction with biological systems. FASEB 1993; 17:272-81.
73. Smythies J. Redox aspect of signaling by catecholamines and their metabolites. Antioxid Redox Sig 2000; 2:573-83.
74. Forman HG, Cadenas E. eds. Oxidative Stress and Signal Tranduction., New York, Chapman and Hall 1997; 475.
75. Hancock JT. Cell Signalling. Oxford University Press, New York 2005; 296.
76. Veriweij CL, Gringhuis SJ. Oxidants and tyrosine phosphorylation; role of acute and chronic oxidative stress in T- and β-lymphocyte signaling. Antioxid Redox Signal 2002; 5:543-51.
77. Schulze-Osthhoff K, Bauer MK, Vogt M, Wesselborg S. Oxidative stress and signal transduction. Int J Vitam Nutr Res 1997; 67:336-42.
78. Kovacic P, Pozos RS. Cell signaling (mechanism and reproductive toxicity): redox chains, radicals, electrons, relays, conduit, electrochemistry and other medical implications. Birth Defects Res Part C 2006; 78:333-44.
79. Hormuzdi SG, Filippov MA, Mitropoulou G, Monyer H, Buzzone R. Electrical synopsis: a dynamic signaling system that shapes the activity of neuronal networks. Biochim Biophys Acta 2004; 1662:113-37.
80. Kovacic P, Pozos RS, Draskovich CD. Unifying electrostatic mechanism for receptorligand activity. J Recept Signal Transduct 2007; 27:411-32.
81. Neff N, Rossi GB. Mescaline. Am J Pharm Sci Support Public Health 1963; 135:319-27.
82. Diaz J. How Drugs Influence Behavior, Prentice Hall, Englewood Cliffs 1996.
83. Koupilova M, Herink J, Krs O. Influencing of spatial memory in rats by DSP-4 and mescaline. Acta Medica (Hrade Kralove, Czech Republic) 1999; 42:69-72.
84. Hermie L, Gouzoulis-Mayfrank E, Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry 1998; 31:85-91.
85. Oepen G, Harrington A, Hermie L, Botsch H, Fuenfgeld M, Spitzed M. Increased right-hemisphereic (RH) striatolimbic uptake of technetium-99m-HMPAO in mescaline-induced schizophrenic-like psychosis. Nuklearmedizin (Suppl) (Stuttgart) 1989; 25:300-3.
86. Fink H, Oelssner W. LSD, mescaline and serotonin injected into medial nucleus potentiate apomorphine hypermotility. Eur J Pharmacol 1981; 75:289-96.
87. Aghajanian GK, Foote WE, Sheard MH. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Expt Therap 1970; 171:178-87.
88. Mokler DJ, Rech RH. Behavioral effects of intracerebroventricular administration of LSD DOM, mescaline or lisuride. Pharmacol Biochem Behav 1984; 21:281-7.
89. Torre E, Carbonatto P, Torre M. Effect of mescaline on cerebral cholinesterases and the exploring behavior of rats. Bollet Soc Ital Biol Speriment 1979; 55:1509-15.